Nascent Biotech, Inc. (OTCMKTS:NBIO) Short Interest Down 99.3% in November

Nascent Biotech, Inc. (OTCMKTS:NBIO) was the recipient of a significant drop in short interest in the month of November. As of November 30th, there was short interest totalling 100 shares, a drop of 99.3% from the November 15th total of 13,900 shares. Based on an average daily volume of 41,800 shares, the short-interest ratio is presently 0.0 days.

Nascent Biotech Price Performance

OTCMKTS NBIO traded up $0.01 during trading hours on Friday, reaching $0.06. The company’s stock had a trading volume of 145,835 shares, compared to its average volume of 99,598. Nascent Biotech has a fifty-two week low of $0.03 and a fifty-two week high of $0.21. The company’s 50-day moving average is $0.06 and its two-hundred day moving average is $0.06.

About Nascent Biotech

Nascent Biotech, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of various forms of cancer. It is developing Pritumumab, a drug to treat patients with brain cancer malignancies, such as glioblastoma and malignant astrocytoma, as well as epithelial cancers, including lung, breast, colon, brain, and pancreas cancer.